J
Javier P. Gisbert
Researcher at Autonomous University of Madrid
Publications - 1076
Citations - 39753
Javier P. Gisbert is an academic researcher from Autonomous University of Madrid. The author has contributed to research in topics: Helicobacter pylori & Inflammatory bowel disease. The author has an hindex of 95, co-authored 990 publications receiving 33726 citations. Previous affiliations of Javier P. Gisbert include Services Hospital & University of Alcalá.
Papers
More filters
Journal ArticleDOI
Helicobacter pylori and bleeding peptic ulcer: what is the prevalence of the infection in patients with this complication?
TL;DR: A meta-analysis comparing the effect of H. pylori eradication versu~ long-term maintenance antisecretory therapy in the prevenlion ofrecurrenl GIR from P and the true influence of NSAIOs on the prevalence of II.
Journal ArticleDOI
Ranitidine bismuth citrate therapy regimens for treatment of Helicobacter pylori infection: a review.
Journal ArticleDOI
Helicobacter pylori infection in a healthy population in Spain
C. Martín-de-Argila,Boixeda D,Rafael Cantón,Mir N,L. De Rafael,Javier P. Gisbert,Arocena C,A García Plaza +7 more
TL;DR: In this article, the seroprevalence of Helicobacter pylori infection in healthy individuals in Spain and its relationship with different epidemiological features was determined using a large group of healthy individuals without ulcer disease antecedents or other gast
Journal ArticleDOI
Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry.
Marisa Iborra,B. Beltrán,Agnès Fernández-Clotet,Alexandra Gutierrez,Beatriz Antolín,José María Huguet,R de Francisco,Olga Merino,Daniel Carpio,Santiago García-López,Francisco Mesonero,Pablo Navarro,R Ferreiro-Iglesias,Ana Yaiza Carbajo,Miguel Rivero,Javier P. Gisbert,M C Piñero-Pérez,David Monfort,Luis Bujanda,M F García-Sepulcre,A Martín-Cardona,Fiorella Cañete,Carlos Taxonera,E. Domènech,Pilar Nos +24 more
TL;DR: This is the first study to show the real-world effectiveness and safety of ustekinumab administered according to the recommended induction regimen in a cohort of highly refractory Crohn's disease patients.
Journal ArticleDOI
Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry
María Chaparro,Ana Garre,Francisco Mesonero,Cristina Rodríguez,Manuel Barreiro-de Acosta,J Martínez-Cadilla,María T Arroyo,Noemí Manceñido,Monica Sierra-Ausin,Isabel Vera-Mendoza,María José Casanova,Pilar Nos,C González-Muñoza,Teresa Torrano Martínez,Maia Boscá-Watts,M Calafat,David Busquets,Eva Girona,Jordina Llaó,María Dolores Martín-Arranz,M Piqueras,Laura Ramos,G Suris,Fernando Bermejo,Ana Yaiza Carbajo,Diego Casas-Deza,Agnès Fernández-Clotet,María Josefa Bernalte García,Daniel Ginard,Ana Gutiérrez-Casbas,Luis Hernández,Alfredo J. Lucendo,Lucía Márquez,Olga Merino-Ochoa,Francisco J Rancel,Carlos Taxonera,Antonio López Sanromán,Saioa Rubio,Eugeni Domènech,Javier P. Gisbert +39 more
TL;DR: Tofacitinib is effective and safe in UC patients in real practice, even in a highly refractory cohort, and a relevant proportion of patients discontinue the drug over time, mainly due to primary failure.